NCT03156738

A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers

A Randomised, Double-blind, Placebo-controlled, Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of MT-2990 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and immunogenicity of MT-2990 in healthy male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MT-2990	Subjects will receive a single IV dose of MT-2990
DRUG	Placebo	Subjects will receive a single IV dose of placebo

Timeline

• Start date: 2017-05-17
• Primary completion: 2017-12-29
• Completion: 2017-12-29
• First posted: 2017-05-17
• Last updated: 2018-01-18

Locations

1 site across 1 country: Netherlands